Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
12/2005
12/15/2005US20050277678 5-(4-Fluorophenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole; prostaglandin and cyclooxygenase inhibitor; antiinflammatory, analgesic, and antipyretic agent
12/15/2005US20050277660 Novel tetrahydroquinoline derivatives
12/15/2005US20050277646 N-[4-({5-(4-fluorophenyl)-4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}oxy)-1,3-benzothiazol-2-yl]acetamide; vanilloid (capsaicin) receptor antagonist/agonist; antiinflammatory, analgesic, antiarthritis, antirheumatic; diseases involving sensory nerve function
12/15/2005US20050277627 Colchinol derivatives as vascular damaging agents
12/15/2005US20050277617 Comprises an amino sugar and trehalose
12/15/2005US20050277609 Immunostimulatory nucleic acid molecules
12/15/2005US20050277606 Administering by direct injection into heart an expression vector comprising a nucleic acid sequence encoding AOP-1 operably linked to a promoter, wherein expression of nucleic acid sequence within cells of heart enhances production of AOP-1, protecting against myocardial cell death
12/15/2005US20050277604 Immunostimulatory nucleic acid molecules
12/15/2005US20050276853 Chronotherapeutic dosage forms and methods of treatment using chronotherapy
12/15/2005US20050276843 An aerosol drug delivery device containing PTH, cyclodextrin, and didecanoylphophatidylcholine that provides droplets of 25 to 700 microns in size; improved bioavailability; osteoporosis
12/15/2005CA2563697A1 Ozonized pharmaceutical composition and method
12/14/2005EP1605040A1 Monocyte-origin multipotent cell momc
12/14/2005EP1604984A1 Water-soluble phenylpyridazine derivative and medicine containing the same
12/14/2005EP1604983A1 Receptor antagonist
12/14/2005EP1604982A1 Intermediates for the preparation of piperidine derivatives useful as modulators of chemokine receptor activity
12/14/2005EP1604674A2 Use of myoblasts in the manufacture of a medicament for treating stress urinary incontinence
12/14/2005EP1604651A1 Transdermal patches and methods for delivering testosterone
12/14/2005EP1604017A2 Cell preparation and use of the preparation for treating joints and cartilage defects, and methods for the production thereof
12/14/2005EP1603917A1 Immunomodulating heterocyclic compounds
12/14/2005EP1603896A2 Cxcr3 antagonists
12/14/2005EP1450786B1 Isoflavone concentrate and method for production thereof
12/14/2005EP1438290B1 Cyclohept b!indole derivatives as spla2 inhibitors
12/14/2005EP1416944B1 Composition for treatment of articular cartilage damage
12/14/2005EP1261583B1 INHIBITORS OF THE ICE/Ced-3 FAMILY OF CYSTEINE PROTEASES
12/14/2005EP1242104B1 Process of obtaining thylakoids from plants, pure thylakoids and use thereof
12/14/2005EP1112255B1 4,4-biarylpiperidine derivatives with opioid receptor activity
12/14/2005CN1708478A P-(sulfonyl)-aryl and heteroaryls amines
12/14/2005CN1706838A Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
12/14/2005CN1706824A Compound as CCR5 agonist
12/14/2005CN1231474C Salts of aiso thiazole-4-carboxamide and their use as anti-hyperproliferatin agents
12/14/2005CN1231473C Substituted arylpyrazines
12/14/2005CN1231471C 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhbitors of cell-cycle kinases
12/14/2005CN1231459C Novel aminobenzophenones
12/14/2005CN1231458C Novel aryloxy-alkyl-dialkylamines compound
12/14/2005CN1231253C Chinese medicine composition for treating intervertebral disc osteoproliferation
12/14/2005CN1231246C Medicinal liquid for activating meridians
12/14/2005CN1231237C Medicine for treating hyperosteogeny
12/14/2005CN1231235C Bolus for eliminating arthralgia and activating energy flow in channels and collaterals and its preparing method
12/14/2005CN1231215C (Imidazol-5-yl) methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
12/14/2005CN1231212C Multicyclic compounds which inhibit beukocyte adhesion mediated by VLA-4
12/13/2005US6974836 Diamines as modulators of chemokine receptor activity
12/13/2005US6974831 sPLA2 inhibitors
12/13/2005US6974828 3-((2-((3-((Amino(imino)methyl)amino)benzoyl)amino)phenyl)sulf anyl)- 3-(3-pyridinyl)propanoic acid, for example; angiogenic inhibitors; antitumor, -carcinogenic, -metastatic, -diabetic, -arthritic and inflammatory agents; bone disorders
12/13/2005US6974826 such as 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxybenzylidene-2,4-thiazolidinedione; Hodgkin's disease
12/13/2005US6974822 Treating osteoarthritis or rheumatoid arthritis
12/13/2005US6974817 CCR1 receptor antagonists; inhibitors of MIP-1 alpha (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells; macrophage inflammatory protein (MIP)
12/13/2005US6974813 For therapy of perioperative myocardial ischemic injury in mammals, including humans
12/13/2005US6974812 such as 2-chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide; purinergic receptors (P2x7 E); for treatment of interleukin-1 associated disorders (rheumatoid arthritis)
12/13/2005US6974809 Inhibitors of interleukin 1-β converting enzyme
12/13/2005CA2280151C Arylsulfonyl hydroxamic acid derivatives
12/13/2005CA2234066C Substituted imidazoles having anti-cancer and cytokine inhibitory activity
12/10/2005CA2507847A1 Prostaglandin reductase
12/10/2005CA2507738A1 Modulation of peroxisome proliferator-activated receptors
12/08/2005WO2005116253A1 Probe for diagnosis of marfan’s syndrome and method of screening with the probe
12/08/2005WO2005116056A1 Hla-a24- or hla-a2-binding peptide of parathyroid hormone-related protein
12/08/2005WO2005116002A2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
12/08/2005WO2005115453A2 Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
12/08/2005WO2005115441A2 Compositions and methods for enhanced mucosal delivery of parathyroid hormone
12/08/2005WO2005115408A1 Method of controlling the proliferation of vascular endothelial cells and inhibiting lumen formation
12/08/2005WO2002066494A3 Identification and cloning of a novel human gene, ret16, involved in the intracellular signaling cascade
12/08/2005US20050272931 Vanilloid receptor ligands and their use in treatments
12/08/2005US20050272817 Dermatological use and a dermatological preparation
12/08/2005US20050272801 Isoprenoid pathway inhibitors for stimulating cartilage growth
12/08/2005US20050272789 Triazole-derived kinase inhibitors and uses thereof
12/08/2005US20050272783 Amino acids with affinity for the alpha2delta-protein
12/08/2005US20050272761 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
12/08/2005US20050272745 Novel piperidine and piperazine derivatives
12/08/2005US20050272739 N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
12/08/2005US20050272718 Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
12/08/2005US20050272709 tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death
12/08/2005US20050272708 phosphoinositol ether lipid analogues and bioisosteres thereof;serine/threonine kinase (protein kinase B (PKB)) inhibitor; antitumor and anticarcinogenic agent; decreasing phosphorylation, increasing apoptosis in a tumor cell, and inhibiting pleckstrin homology (PH) domain binding
12/08/2005US20050272707 Method for preventing or reducing secondary fractures after hip fracture
12/08/2005US20050272705 Method of adminstering bisphosphonates
12/08/2005US20050272669 treatment of disease associated with hyperglycemia: diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity; e.g. -[(4-{3-[N-(Carbamoylmethyl)-N-(methanesulfonyl)amino]-propoxy}-2-methylphenyl)methyl]-3-( beta -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole
12/08/2005US20050272647 Arthrodial cartilage extracellular matrix degradation inhibitor
12/08/2005US20050272633 Derivatives of the nf-kappab inducing enzyme, their preparation and use
12/08/2005US20050272077 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
12/08/2005US20050272036 Ketones
12/08/2005US20050271751 Active principle which is capable of inducing the conversion of inactive TGFb-latent into active TGFb
12/08/2005US20050271743 Treatment of inflammatory skin conditions
12/08/2005US20050271717 Dry-granulated dosage forms of tablets or capsules; preparation by compressing the mixture, milling, grinding or sieving the compressed material; hypercholesterolemia, hyperlipidemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's disease
12/08/2005US20050271637 BMP-2 estrogen responsive element and methods of using the same
12/08/2005DE60017281T2 Nomegestrolacetat und östrogen enthaltende Hormonzusammensetzung und ihre Verwendung Nomegestrol acetate and estrogen hormone-containing composition and its use
12/08/2005CA2772029A1 Compositions and methods for bone formation and remodeling
12/08/2005CA2771951A1 Compositions and methods for bone formation and remodeling
12/08/2005CA2567942A1 Hla-a24- or hla-a2-binding peptide of parathyroid hormone-related protein
12/08/2005CA2567405A1 Use of morphogenic proteins for treating cartilage defects
12/08/2005CA2567056A1 Compositions and methods for enhanced mucosal delivery of parathyroid hormone
12/08/2005CA2562243A1 Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
12/07/2005EP1602931A1 SR-A antagonists
12/07/2005EP1602665A1 Physiologically active peptides and drugs containing the same
12/07/2005EP1602658A1 Tricyclic pyrazole derivatives as cannabinoid receptor antagonists
12/07/2005EP1602656A1 Pyrazole derivatives having affinity for cb1 and/or cb2 receptors
12/07/2005EP1602655A1 Benzofuran derivative
12/07/2005EP1602647A1 Novel compound having 4-pyridylalkylthio group as substituent
12/07/2005EP1602380A1 Preventive/remedy for diseases in upper digestive tract
12/07/2005EP1602379A1 Botulinum toxin B for treating spastic muscle
12/07/2005EP1602370A2 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
12/07/2005EP1601673A1 Novel fused heterocycles and uses thereof
12/07/2005EP1601646A2 2-substituted vitamin d analogues and their therapeutic uses
1 ... 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 ... 820